Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
49
datasets available to search
ShareScore release 0.9.0
Dataset results
49 results for “BCMA CAR-T Therapy”
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT04272151. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
ClinicalTrials.gov study NCT07200089. IPD Sharing: YES. Countries: 1. Publications: 0.
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
ClinicalTrials.gov study NCT07003568. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
ClinicalTrials.gov study NCT04271644. IPD Sharing: NO. Countries: 1. Publications: 0.
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT05722418. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.gov study NCT06759181. IPD Sharing: NO. Countries: 1. Publications: 0.
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
ClinicalTrials.gov study NCT04776330. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
ClinicalTrials.gov study NCT07152223. IPD Sharing: NO. Countries: 1. Publications: 0.
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT07340853. IPD Sharing: NO. Countries: 1. Publications: 0.
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT06644443. IPD Sharing: NO. Countries: 1. Publications: 0.
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
ClinicalTrials.gov study NCT05846737. IPD Sharing: NO. Countries: 1. Publications: 0.
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
ClinicalTrials.gov study NCT04318327. IPD Sharing: NO. Countries: 4. Publications: 0.
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
ClinicalTrials.gov study NCT05243212. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
ClinicalTrials.gov study NCT06794008. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
ClinicalTrials.gov study NCT05979363. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
ClinicalTrials.gov study NCT06548607. IPD Sharing: NO. Countries: 1. Publications: 0.
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
ClinicalTrials.gov study NCT07003555. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
ClinicalTrials.gov study NCT06515262. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
ClinicalTrials.gov study NCT07250269. IPD Sharing: YES. Countries: 1. Publications: 0.
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
ClinicalTrials.gov study NCT04637269. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.